Applicat

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10598570
Filing Date		2006-09-11
First Named Inventor Keiji N		Naruse et al.
Art Unit		
Examiner Name		
Attorney Docket Numb	or	116566 00005

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	4789601		1988-12-06	Banes	
	2	4822741		1989-04-18	Banes	
	3	4839280		1989-06-13	Banes	
	4	5217899		1993-06-08	Shapiro et al.	
	5	6107081		2000-08-22	Feeback et al.	
If you wish	h to a	dd additional U.S. Pater	t citatio	n information pl	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					
If you wish	h to a	d additional U.S. Publis	hed An	nlication citation	n information please click the Adi	hutton Add

FOREIGN PATENT DOCUMENTS

### 

Pages,Columns,Lines

Name of Patentee or

Examiner Initial*	No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Applicant of cited Document	where Relevant Passages or Relevant Figures Appear	Τs
	1	2003-61642	JP		2003-04-03	Takagi et al.		
	2	02/46365	wo		2002-06-13	Banes		
	3	1428869	EP		2006-12-07	Takagi et al.		
If you wis	h to a	dd additional Foreign F	atent Document	citation	information pl	lease click the Add butto	n Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	miner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), published.				Ţ5			
1 NARUSE, K. et al., "Involvement of SA Channels in Orienting Response of Cultured Endothelial Cells to Cyclic Stretch", American Physiological Society, (1998), H1532 to H1538 2 NAKAGAKI, M. et al., "Development of a Biastial Cyclic Stretching Mechanism and Analysis of Mechanical Response of Vasoular Endothelial Cells.", Bio Frontier Koenical Koen Ronbundhu, (2003), Vol. 14, 7 to 8  NARUSE, K. et al., "Similen Shigenife to Keikkan Nathi Saibo, Sheiten Shinten Shigein in Hoho to Saibo Oto no Saibeschin, Japanese Journal of Medical Electronics and Biological Engineering, (1996), Vol. 36, No. 3, Pages 287 to 2004 3 SOKABE, M. and NARUSE, K., "Methods of Stretching Cultured Cells: Their Advantages and Disadvantages," The Tissue Culture, (1996), Vol. 22, No. 10, pages 413 to 417.				al Cells to Cyclic				
	5	CLARK, C.B. et al., "Un	iaxial Strain System	m to Inve	estigate Strain R	tate Regulation in Vitro" Re	wines of Scientific	П

# | Application Number | 10596570 | Fing Date | 2006-09-11 | Fing Date | 2006-09-11 | Fing Date | 2006-09-11 | Find Date |

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

1 See Kint Cotes of USPTO Patent Documents at Invent USPTO CODY or MPEP 901.04. Enter of tice that issued the document, by the Involved (WIPO) Spander S13. If "explanates patent documents, the indication of the year of the inspire or precise to see and under the patent document, and occurrent or the parent document or the parent patent occurrent." A find of document by the appropriate symbols as andicated on the document under WIPO Standard S1.16 if possible. Spplicant is to place a check mark here if English languages translation is stateded.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10598570
Filing Date			2006-09-11
	First Named Inventor Keiji I		Varuse et al.
	Art Unit		
	Examiner Name		
	Attorney Docket Number		116566 00005

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sea 97 CFR 137(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 159(c) more than three months prior to the filing of the information disclosure statement. Sex 37 CFR 137(c)(c)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

\_ ....

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Gavin J. Milczarek-Desai/	Date (YYYY-MM-DD)	2006-12-11
Name/Print	Gavin J. Milczarek-Desai	Registration Number	45801

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 122 and 3T CFR 1.14. This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operament of Commence, P. 0. Box 1450, Alexandris, V.3.231.14450, D. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.14450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.